Friedrich von Bohlen und Halbach, Ph.D. (Chairman)
Friedrich von Bohlen, Ph.D., is co-founder and managing director of dievini Hopp BioTech holding GmbH & Co. KG. dievini manages the biotech activities and investments of SAP co-founder Dietmar Hopp and his family. Dr. von Bohlen holds a graduate degree (Diplom) in Biochemistry from the University of Zurich and a Ph.D. in Neurobiology from the Swiss Federal Institute of Technology in Zurich, Switzerland. From 1992 to 1997, he worked for Fresenius AG, FAG Kugelfischer, and WASAG-Chemie AG. In 1997, he founded LION bioscience AG (now SYGNIS Pharma AG) and served as the company’s CEO for six years. In addition to serving as Chairman of the Supervisory Board for Apogenix, Dr. von Bohlen holds several other board positions in dievini Hopp portfolio companies.
Prof. Peter Krammer, M.D.
Prof. Peter Krammer, M.D., is Head of the Division of Immunogenetics in the Tumor Immunology Program at the German Cancer Research Center (DKFZ) and a member of the Board of Directors of the National Center for Tumor Diseases (NCT) in Heidelberg, Germany. He studied medicine at the University of Freiburg, Germany, in St. Louis, MO, USA, and in Lausanne, Switzerland. Prof. Krammer is one of the world’s most renowned apoptosis researchers and has received numerous prestigious awards, including the Robert Koch Prize, the German Cancer Award, the Kitasato-Behring Prize, the Avery-Landsteiner Prize, the Ernst Jung Prize, and the Order of Merit of the Federal Republic of Germany.
Martin Buermann, J.D.
Martin Buermann, J.D., is partner of the law firm Rittershaus in Mannheim, Germany. He studied law at the University of Heidelberg and obtained his J.D. from the University of Augsburg in Germany in 1991. In 1998, he received his admission to practice law. Buermann specializes in corporate law, private equity transactions, and trade sales. He has been advising biotechnology companies since 1999.
Mathias Hothum, Ph.D.
Mathias Hothum, Ph.D., is owner of HMM-Consulting and managing director of dievini Hopp BioTech holding GmbH & Co. KG. He received his graduate degree in economics from the University of Mannheim and his doctorate degree from the University of Magdeburg in Germany. Over the past 20 years, he has gained extensive experience as an economist in the fields of healthcare, health services, and life sciences. He specializes in pricing, reimbursement, and in the evaluation of medium-sized and publicly traded companies. At dievini, his focus is on managerial accounting and strategic planning for portfolio companies.
Prof. Josef Puchta, Ph.D.
Prof. Josef Puchta, Ph.D., has been serving as Commercial Director of the German Cancer Research Center (DKFZ) in Heidelberg, Germany, since August 1996. He studied economics at the Universities of Augsburg and Erlangen-Nuremberg, and received his doctorate degree (Dr. rer. pol.) from the University of Oldenburg in Germany. In 1983 and 1984, Prof. Puchta conducted research in Canada. From 1987 to 1992, he worked for the German Foundation for International Development in Berlin and at the Senate Department for Economics and Technology of the State of Berlin. From 1992 to 1996, he served as Administrative Director of the German Institute of Human Nutrition in Potsdam, Germany. In January 2011, he was appointed Honorary Professor at the University of Applied Sciences in Mannheim, Germany.
Hartmut Voss, Ph.D.
Hartmut Voss, Ph.D., is responsible for the scientific evaluation of biotechnology and biopharmaceutical companies at dievini Hopp BioTech holding GmbH & Co. KG. Following his studies in biology at the University of Kaiserslautern, he obtained his Ph.D. from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. In 1997, he co-founded LION bioscience AG (now SYGNIS Pharma AG), where he held various senior management positions.